1.1Dimethylsilyl group at X
The silicon atom forms a single bond to each of the two atoms flanking X. Two methyl groups complete its four bonds, and the silicon atom occupies one position in the ring.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The silicon atom forms a single bond to each of the two atoms flanking X. Two methyl groups complete its four bonds, and the silicon atom occupies one position in the ring.
The nitrogen at X bonds directly to a carbon of the six-membered aromatic ring. The phenyl group projects from the core as a rigid, planar substituent.
A chain of six methylene groups joins the two substituent bonds at the shared carbon. The chain and shared carbon form a cycloheptane ring that meets the core at that single atom.
The carbon at Y bonds to the two neighboring ring atoms and to hydrogen. It contributes one electron to the aromatic π system, and the nitrogen at Z retains its lone pair.
Fluorine forms a direct bond to the ring carbon at Y. The carbon remains part of the aromatic π system, and the carbon–fluorine bond places a local dipole at that position.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A chromatographic stationary phase test uses two tricyclic compounds with the same core and different terminal ring groups. One carries a phenyl group at R18 and the other carries a pyridinyl group at R18, with direct attachment in both compounds. Separate injections establish peak identities, and a mixed injection measures the retention selectivity of the stationary phase.
A methylene group replaces the oxygen linker between the tricyclic core and the terminal phenyl ring. The resulting side chain attaches to the core through a carbon–carbon bond and has the connectivity core–CH2–phenyl. A matched pair uses the same core stereochemistry and peripheral substituents to isolate the effect of the linker on chromatographic retention.
A spirocycloheptane occupies the core position where X is a substituted carbon. A six-methylene tether connects both substituent bonds of that carbon, forming a seven-membered carbocycle that shares one atom with the tricyclic core. A matched series uses four-, five-, and six-methylene tethers to compare five-, six-, and seven-membered spiro rings under the same measurement conditions.
A preparative liquid chromatograph connects through an ultraviolet detector to a triggered fraction collector. The injection contains a mixture of tricyclic compounds with distinct terminal ring groups. An analytical scouting run identifies the collection windows, and the preparative system offsets those windows by the detector-to-collector tubing volume divided by the flow rate.
A humidity-controlled powder X-ray diffractometer holds a crystalline tricyclic solvate in a sample chamber supplied with mixed dry and humid gas streams. The chamber maintains a fixed temperature while relative humidity advances through preset steps. Diffraction patterns collected after equilibration at each step track changes in the crystalline phase as the sample takes up or loses water.
A molecular graph enumerator takes a connection table for a fully specified tricyclic core and a library of side chains with marked attachment atoms. It attaches each side chain, checks valence, and enumerates configurations at unspecified stereocenters. Canonical isomeric representations remove duplicate structures, and each output record stores the core identifier, side-chain identifier, and stereochemical assignment.
R15 is deuterium, and the associated scaffold carbon forms a direct carbon–deuterium bond. The isotope changes the mass at that position while preserving the carbon’s bonding pattern.
The indicated bond is a carbon–carbon double bond, and R6 and R8 are absent. The two carbons have trigonal planar geometry, and the π bond restricts rotation about their shared axis.
L1 is an oxygen atom that forms one single bond to the core and one to R18. With phenyl as R18, the resulting substituent is a phenoxy group attached through oxygen.
R18 is a six-membered phenyl ring with fluorine at the carbon opposite the attachment point. The attachment and fluorine occupy positions 1 and 4 of the ring.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
X and Y are each independently selected from the group consisting of a bond, —NR7—, —CR7R8—, —S(O)m—, ring A is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl are each optionally further substituted by one or more substituents selected from the group consisting of deuterium, alkyl, deuterated alkyl, halogen, amino, nitro, hydroxy, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —(CH2)nOR9, —(CH2)nSR9, —(CH2)B · US 2021/0032249 A1 · claim 1
R6 is selected from hydrogen, cyano, alkyl or haloalkyl;A · US 2015/0218187 A1 · ¶
Ra and Rb are independently selected from the group consisting of hydrogen, —OR7, halogen, haloalkyl, perhaloalkyl and alkyl; or Ra and Rb taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally have additional heteroatoms selected from O, N or S; p=0-2; n=0-4A · US 2015/0218187 A1 · ¶
The above substituents can be bonded to different carbon atoms to form a carbon chain, or can be bonded to one carbon atom to form a cycloalkyl.B · US 2021/0032249 A1 · ¶ 114
* represents point of attachment to L2. rings A and B represent a spirocyclic ring system wherein, A and B are same or different and independently represents a three to eight membered ring which may be saturated or partially unsaturated optionally having up to four heteroatoms selected from O, N or S; ring C is absent or is 6 membered aromatic or heteroaromatic ring system; ring D is selected from cycloalkyl, aryl, heterocyclyl or heteroaryl; rings E represents a 5-12 membereA · US 2015/0218187 A1 · ¶
L1, L2, L3, L4 and L5 are independently absent or is C1-4 alkylene wherein one or more methylene groups is optionally replaced by hetero atoms or groups such as —O—, —S(O)p—, —N(R6)—, —C(O)—, —C(S)— or —(CRaRb)—; alkylene is optionally substituted with hydroxy, amino, aminoalkyl, cyano, halogen, haloalkyl, perhaloalkyl, carboxy, carboxyalkyl, alkylcarboxy, alkoxy, hydroxyalkyl, alkoxyalkyl, alkoxyalkoxy or alkyl;A · US 2015/0218187 A1 · ¶
ring A is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl are each optionally further substituted by one or more substituents selected from the group consisting of deuterium, alkyl, deuterated alkyl, halogen, amino, nitro, hydroxy, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —(CH2)nOR9, —(CH2)nSR9, —(CH2)nC(O)R9, —(CH2)nC(O)OR9, —(CH2)nS(O)mR9, —(CH2)nNR10R11, —(CH2)nC(O)NR10R11, —(CH2)nC(O)NHR10, —(CH2)nB · US 2021/0032249 A1 · ¶ 11
R1, R2, R3, R4 and R5 are independently selected from hydrogen, halo, cyano, nitro, —(CRaRb)nOR7, —(CRaRb)nC(O)R7, —(CRaRb)nSR7, —(CRaRb)nCOOR7, —(CRaRb)nNR8R9, —(CRaRb)nC(O)NR8R9, —(CRaRb)nNR8C(O)OR7, —(CRaRb)nNR8C(O)NR8R9, —NR8S(O)2R7, —S(O)pR7, —SO3H, —S(O)2NR8R9, azido, oxo, thiocarbonyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, cyanoalkyl, cyanoalkylcarbonyl, haloalkyl, perhaloalkyl, haloalkoxy, perhaloalkoxy, alkoxyalkoxy, alkoxyalkoxyalkyl, cycloalkyl, cycloalkenyl, cycloaA · US 2015/0218187 A1 · ¶
or, R3 and R4 are bonded to form a heterocyclyl or heteroaryl, any two substituents on the heterocyclyl or heteroaryl can form a cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally further substituted by one or more substituents selected from the group consisting of deuterium, alkyl, deuterated alkyl, haloalkyl, halogen, amino, nitro, hydroxy, cyano, alkenyl, alkynyl, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclB · US 2021/0032249 A1 · ¶ 29
An empty cell means only that no passage was reproduced there.
Therefore, there remains a need for discovering novel DGAT1 inhibitors possessing desirable properties such as pharmacokinetic/dynamic and or physicochemical and/or other drug like profiles to advance into clinics.A · US 2015/0218187 A1 · ¶ 6
These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of acyl CoA diacyl glycerol acyltransferase 1 (DGAT1).A · US 2015/0218187 A1 · ¶ 1
At present, there are no drugs approved for treating NASH.B · US 2021/0032249 A1 · ¶ 4
ASK1 inhibitors have great potential for the clinical treatment of NASH, and have potential valuable application in the treatment of other diseases including neurodegenerative diseases, cardiovascular diseases, inflammation, autoimmune metabolic diseases and the like.B · US 2021/0032249 A1 · ¶ 4
patent.fyi, US 2026/0356851 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356851/, SHA-256 3feff9ffe0befbf389ebdc6358f6eb2070ddc2bb7f8e2c44e5c1f8eb41702068